Atriance launched for lymph cancer

GSK has launched Atriance (nelarabine) for the treatment of patients with T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded, or has relapsed, following treatment with at least two chemotherapy regimens.

Further information: GSK 0800 221441

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more